POTENSI TERAPI PROBIOTIK SEBAGAI TERAPI ALZHEIMER MELALUI GUT-BRAIN AXIS

  • Nafatasya Ayu Rahmansyah Universitas Mataram

Abstract

ABSTRAK

Alzheimer's disease is a neurodegenerative disease characterized by loss of memory and decreased cognitive function. Symptoms of Alzheimer's disease include confusion, incorrect assessment, irritation, withdrawal, and hallucination. Microbiota Gut-Brain Axis (MGBA) is a complex communication system between GIT, gut microbiota and central nervous system that transmits information to and from the brain and used to treat and improve symptoms of mental disorders with probiotic (live bacteria). The Purpose of this review is to determine relationship between the gut-brain axis and probiotic as a treatment for mental disorders. This study is a research with literature study using Google Scholar, PubMed and Science Direct  with keywords (Alzheimer's) AND (probiotic AND Alzheimer's). The types of articles used are meta analysis, systematic literature review, narrative review and use Indonesian and English free full text publication between 2012-2022. The final articles selected by the authors were 15 journal articles. The literature study found the long-term benefit of using probiotic that can improve health function and development as well as cognitive maturation and diet therapy as a therapy in Alzheimer's disease. The role of probiotic is to improve function and health development and cognitive maturation.

Keywords: Alzheimer’s, Gut-Brain Axis, Probiotics, Diet

References

1. Kumar Thakur A, Kamboj P, Goswami K, Ahuja K. Pathophysiology and management of alzheimer’s disease: an overview. J Anal Pharm Res. 2018;7(2):226–35.
2. Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2021. Alzheimer’s Dement Transl Res Clin Interv. 2021;7(1):1–24.
3. Mörkl S, Butler MI, Holl A, Cryan JF, Dinan TG. Probiotics and the Microbiota-Gut-Brain Axis: Focus on Psychiatry. Curr Nutr Rep. 2020;9(3):171–82.
4. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(8).
5. Rizzi L, Rosset I, Roriz-Cruz M. Global epidemiology of dementia: Alzheimer’s and vascular types. Biomed Res Int. 2014;2014(Figure 1).
6. Garre O-. Epidemiology of Alzheimer’s disease and other dementias. 2018.
7. Vinicius M, De Mello C, Vieira L, Cruz de Souza L, Gomes K, Carvalho M. Alzheimer’s disease: risk factors and potentially protective measures. J Biomed Sci [Internet]. 2019;26(33):1–11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507104/
8. Eid A, Mhatre I, Richardson JR. Gene-environment interactions in Alzheimer’s disease: A potential path to precision medicine. Pharmacol Ther. 2019;199:173–87.
9. Tong BCK, Wu AJ, Li M, Cheung KH. Calcium signaling in Alzheimer’s disease & therapies. Biochim Biophys Acta - Mol Cell Res [Internet]. 2018;1865(11):1745–60. Available from: https://doi.org/10.1016/j.bbamcr.2018.07.018
10. Tiwari S, Venkata A, Kaushik A, Adriana Y, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine . 2019;Jul 2019(14):5541–54.
11. Erin E. Congdon, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Physiol Behav. 2018;176(3):139–48.
12. Ryszard Pluta, S?awomir Januszewski, Marzena U?amek-Kozio?, Stanis?aw J. Czuczwar. Gut microbiota and pro/prebiotics in Alzheimer’s Disease. Aging (Albany NY) [Internet]. 2020;12(6):5539–50. Available from: 10.18632/aging.102930
13. Arora K, Green M, Prakash S. The Microbiome and Alzheimer’s Disease: Potential and Limitations of Prebiotic, Synbiotic, and Probiotic Formulations. Front Bioeng Biotechnol. 2020;8(December):1–17.
14. Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer’s disease. Sci Rep [Internet]. 2017;7(1):1–11. Available from: http://dx.doi.org/10.1038/s41598-017-13601-y
15. Kowalski K, Mulak A, Words K. Brain-Gut-Microbiota Axis in Alzheimer ’ s Disease. 2019;25(1).
Published
2022-06-30
Section
Literature Review